Targeted therapy in older patients with solid tumors.

Area of Science:

• Oncology
• Pharmacology
• Geriatrics

Background:

• Personalized medicine in cancer therapy is driven by targeted therapies and a deeper understanding of tumor heterogeneity.
• Approved targeted drugs span various classes, including tyrosine kinase inhibitors, mTOR inhibitors, and therapies targeting HER2, BRAF mutations, EGFR, and VEGF.

Purpose of the Study:

• To review approved targeted therapies for cancer treatment.
• To analyze the applicability of these therapies in elderly patients, considering the lack of specific clinical trials.
• To provide therapeutic recommendations for older adults undergoing targeted cancer therapy.

Main Methods:

• Review of approved targeted drugs across different therapeutic classes.
• Analysis of existing clinical trial data, acknowledging limitations regarding elderly participant representation.
• Synthesis of information to inform geriatric-specific treatment considerations.

Main Results:

• Targeted therapies represent a significant advancement in cancer treatment.
• Most data on targeted therapies are extrapolated from trials not specifically designed for elderly populations.
• Older patients in clinical trials are often underrepresented, potentially limiting generalizability.

Conclusions:

• Elderly patients require careful patient selection and geriatric evaluation for targeted cancer therapy.
• Appropriate drug selection, dosing, and monitoring are essential for safe and effective treatment in older adults.
• Despite data limitations, targeted therapies can be a major step forward for older cancer patients when administered with care.